SUMMARY Cloning of a DNA segment including the translocation breakpoint in a female with an X;21 translocation and X linked muscular dystrophy has led to identification of three subclones which detect polymorphic markers. The alleles of these markers, XJ1 1, XJ1-2, and XJ2 2, are in strong linkage disequilibrium. Linkage analysis in 31 families with Duchenne or Becker muscular dystrophy has shown recombination within the XJ segment in one case, and recombination of DMD with both the XJ segment and the pERT87 segment in a second, but has revealed no recombination between the XJ and pERT87 segments. The XJ markers increase the proportion of DMD and BMD families that are informative for carrier detection and prenatal diagnosis, but in view of the risk of recombination they must be used with caution. The site(s) of the DMD mutation(s) relative to the XJ and pERT87 markers, and the detailed molecular structure of the DMD region, remain to be determined.
The locus for Duchenne muscular dystrophy (DMD) has been mapped to the short arm of the X chromosome at band Xp2l, by family studies and by analysis of structural abnormalities of the X chromosome.1-10 The locus for Becker muscular dystrophy (BMD), a disorder overlapping DMD phenotypically and distinguished from DMD arbitrarily on the basis of its milder clinical course, has also been mapped to Xp2l,l13 but there is still uncertainty as to whether the mutations responsible for DMD and BMD are allelic or occur within closely linked loci.
A number of translocations that have been ascertained in females with DMD or BMD are of particular interest, as they have all involved a breakpoint in Xp2l and reciprocal translocation with an autosome. Disruption of the Xp2l muscular dystrophy locus by the translocation, coupled with non-random inactivation of the other (normal) X chromosome, seems to be responsible for the Received for publication 28 July 1986 . Accepted for publication 4 August 1986. disease in these girls. Although all the known translocation exchange points are in band Xp2l, high resolution cytogenetic analysis of several cases has suggested heterogeneity of the exchange points within this rather large band.14 One of the translocation females is a Belgian woman with a form of muscular dystrophy originally diagnosed as DMD, who was found to have an X;autosome translocation, t(X;21) (p21;pl2), with one exchange point near the Duchenne locus in Xp2l and the other within a cluster of ribosomal RNA genes at 21pl2. 4 15 Sequences from the ribosomal RNA genes have been used as probes to clone a DNA segment spanning the translocation breakpoint. '6 Within the X chromosomal portion of the initial clone XJ1, two subclones, XJ1P1 and XJ1-2, from the centromeric side of the junction have been found to detect restriction fragment length polymorphisms (RFLPs). By 'chromosome walking' along a normal X chromosome, an adja-been identified with subclone XJ2-2 of that segment. In this report we describe the linkage relationships of these three RFLPs to one another, to DMD (or BMD), and to several other Xp markers within close linkage distance of the Xp2l muscular dystrophy gene, which we will refer to as DMD.
Materials and methods

CHROMOSOME WALKING AND RFLP ANALYSIS
Bacteriophage clones overlapping XJ1 were isolated from a human DNA recombinant library constructed in X charon 3517 from size selected (13 to 20 kb) partially Sau3A digested DNA derived from a female XXXX cell line (GM1202, Camden Repository). The unique sequence probes XJ1-1 and XJ1-2 from the junction clone XJ116 were used to screen nitrocellulose lifts from primary plates of the library by standard technology,'8 and hybridising phage were plaque purified through three rounds of selection. All clones were restriction mapped with BamHI, EcoRI, XbaI, and HindIII, and the clones containing sequences extending the farthest in the telomeric and centromeric directions were designated XJ2 and XJ3 respectively. Fragments from these walk clones were subcloned into either pUC1919 or pSP65.20
In order to screen RC8, D2, 99-6, C7, pERT87-8 (two polymorphisms), pERT87-1 (two polymorphisms), 754, and L1-28. The probes used, the enzyme that reveals polymorphism in each case, the fragment lengths, the allele frequencies, and some linkage information about these markers have been described Table 2 shows the fragment lengths, allele frequencies, and heterozygote frequencies of the three polymorphic markers XJ1-1, XJ1*2, and XJ2-2. For each of these polymorphisms, at least 40% of the women studied were heterozygous.
LINKAGE DISEQUILIBRIUM WITHIN XJ
The three markers XJ1-1, XJ1-2, and XJ2-2 are in pronounced linkage disequilibrium with one another (table 3) . Two haplotypes, one with the common allele at each locus, and the antithetical combination with the rare allele at each locus, account for 85% of Table 4 summarises the number of informative meioses and the number of recombinations observed in pairwise combinations of DMD and the XJ haplotype with one another and each with probes RC8, D2, 99-6, C7, the pERT87-1/87-8 haplotype, 754, and L128. The cluster DMD-pERT87-XJ lies between C7 and 754, but the arrangement of these three loci in relation to one another cannot be inferred from the recombination data alone, although physical mapping has shown that pERT87 is telomeric to XJ (fig 2) .°O 32 We have found two subjects recombinant for DMD and XJ in 45 informative meioses. The relevant pedigrees are presented in fig 3. Pedigree 1 (HSC 14) shows a recombination within the XJ region itself, between the XJ2-2 and XJ1 1 polymorphic sites. This was the only such recombinant among 51 meioses informative for both XJ2-2 and XJ1-1. In this particular family, the mutation segregates with the XJ2-2 marker and separates She is also heterozygous for a more remote distal marker, pXUT23, and again has given both sons the same allele. One interpretation is shown: two recombinations, one between D2 and pERT87 and the other between XJ and 754, in the meiosis giving rise to one son. Alternatively, the D2-pERT87 recombination could have occurred in the meiosis giving rise to one son and the XJ-754 recombination in the meiosis leading to his half-brother. The position of the DMD mutation cannot be determined from this pedigree; although it is drawn in the figure between D2 and pERT87, it could equally well lie between pERT87 and XJ, or between XJ and 754.
No pERT87-XJ recombinants were seen in 41 informative meioses. The lack of recombination in this region contrasts with the relatively high rate of recombination of DMD both with pERT87 (five recombinants in 64 informative meioses) and with XJ (two recombinants in 45 informative meioses).
Discussion
The XJ segment and the polymorphisms recognised within it will be useful in the continuing attempts, in many laboratories, to define the extent of the DMD locus and the nature of the mutations responsible for the disease. They also provide an additional system of markers for carrier detection and prenatal diagnosis. The three probes and XJ2-3, which recognises the same polymorphism as XJ2*2, are available on request for family studies.
Digestion with TaqI alone reveals both the XJ1 -1 and the XJ2*2 markers, which are different enough in the fragment lengths of their alleles to be readable from the same gel. About 50% of the women in our sample are heterozygous for one or both of these two markers. Consequently it is convenient and may occurred in meiosis in his mother I.2 within the XJ segment, between the XJ2-2 and XJI -I polymorphic sites, and DMD segregates with the XJ2-2 allele, indicating that the DMD mutation is distal to XJin this family. Abbreviations: +, dmd, alleles at DMD locus; XJ2-2 alleles (fragment lengths, kb) 6-4, 7-8; XJJ lalleles 31, 3-8; XJI2 alleles 2-0, 17 . In pedigree 2, the linkage phase in the mother 1 is unknown and there are alternative explanations ofthe pedigree (discussed in the text). Markers in sequence from distal to proximal: pXUT23, D2, pER T87-8187-1 haplotype, XJ haplotype, 754. Though shown diltal to the pER T87 markers, the precise location ofthe DMD mutation in this family cannot be determined. Further abbreviations, with enzyme used andfragment lengths (kb) ofalleles: pTA, pERT87-8 BstXI 4-4, TaqI 1-112-7;pERT87-J XmnI 8-7, BstNI 3-1. pTC, pERT87-8 BstXI 2-2, TaqI 1-112-7;pERT87-J XmnI 8-7, BstNI 2*45/0*65.XJA,XJ2-2 6-4,XJIJI 3J,XJ12 2-0.XJB,XJ2-2 7-8,XJIJI 3-8,XJI-2 117. I group.bmj.com on June 20, 2017 -Published by http://jmg.bmj.com/ Downloaded from be sufficient to test possible heterozygotes for XJ1-2 and XJ2.2 alone. The additional chance of finding heterozygosity by subsequent testing for XJ1-2 is only 4%.
The region detected by the pERT87 probes is telomeric to the XJ segment, at an unknown distance from it. In the present study, no recombination was observed between pERT87 and XJ, whereas both pERT87 and XJ show 4 to 8% recombination with DMD. However, there is evidence from the analysis of deletions in DMD patients that pERT87 and XJ are separable,33 and chromosome walking from each one in the direction of the other has not yet revealed any overlap (unpublished observations). The tight linkage may simply be a reflection of their close physical proximity.
The strong linkage disequilibrium among the three XJ markers suggests that recombination is rare in this region, or alternatively that selection favours certain XJ combinations. Consequently, it is unexpected that in one of the two DMD-XJ recombinants we have observed, the recombination is actually within the XJ region, in the 9 kb stretch of DNA between the XJ2-2 and XJ1*1 polymorphic sites. The possibility that recombination is more frequent than expected in the DNA segment associated with DMD has been suggested,30 but one would not expect the pronounced linkage disequilibrium observed within the XJ region if recombination is frequent there. Further information from additional families may show whether the recombination we have observed is a unique event or a characteristic finding.
Pedigree 2 exemplifies the difficulty of accurate prenatal diagnosis without enough family information to indicate the linkage phase in the mother. The mother is heterozygous for each of six markers. An attempt at prenatal diagnosis in her second pregnancy would have revealed discrepancy between the information given by the flanking markers and that given by the pERT87 and XJ markers, and would have shown that in spite of the mother's numerous heterozygous markers, the DMD genotype of her fetus could not be accurately predicted.
We have used presumptive carriers as well as obligate carriers in analysis of our pedigrees and linkage data. We classify a woman as a 'presumptive carrier' on the basis of her high prior probability of being a carrier and serum CK activity raised above the Perhaps the most important problem in the molecular genetics of DMD is the site of the DMD mutation(s) relative to the markers C7, pERT87, XJ, and 754. All recombinants for DMD-pERT87 or DMD-XJ require analysis for flanking markers, to determine on which side of pERT87 and XJ the mutations map. Unfortunately, in pedigree 2, the linkage phase in the mother 1-1 is unknown, and there is a double recombination (or one in each of two affected sons) between D2 and 754. The DMD mutation could be segregating with either of these markers, making the site of the mutation uncertain.
Indeed, the challenge that lies ahead is to learn how the pERT87 and XJ regions can lie close enough to the DMD gene to detect small deletions and reciprocal translocations that cause the disease, yet be sufficiently distant to be separated from the DMD mutation in 4 to 8% of meioses. Clearly, until transcribed sequences in the form of cDNA clones are available, it will not be possible to determine whether the DMD locus is a single gene of very large size, a set of interdependent genes, or a gene located in a segment of DNA with unusual recombinational properties.
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